r-lansoprazole

(R)-Lansoprazole (T 168390) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Levolansoprazole ((S)-Lansoprazole), a proton pump inhibitor, irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 μM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 μM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.

(R)-Lansoprazole-D4 is the deuterium-labeled form of  (R)-Lansoprazole (T1021). This compound is the R-enantiomer of Lansoprazole, a proton pump inhibitor that suppresses gastric acid production. Additionally, Lansoprazole (AG 1749) acts as an inhibitor of neutral sphingomyelinase (N-SMase), functioning as an exosome inhibitor.

Dexlansoprazole-D4 is a deuterated compound of Dexlansoprazole. Dexlansoprazole (T1021) has a CAS number of 138530-94-6. Dexlansoprazole (T1021) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Levolansoprazole-D4 is a deuterated compound of Levolansoprazole. Levolansoprazole (T20714) has a CAS number of 138530-95-7. Levolansoprazole, a proton pump inhibitor, irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 µM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 µM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.